Brokerages Set Omeros Co. (NASDAQ:OMER) Price Target at $22.50

Shares of Omeros Co. (NASDAQ:OMER) have received an average rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $22.50.

Several analysts have recently weighed in on OMER shares. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Rodman & Renshaw initiated coverage on shares of Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 target price on the stock. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. D. Boral Capital initiated coverage on shares of Omeros in a report on Monday. They set a “buy” rating and a $36.00 price target on the stock. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th.

Omeros Stock Down 1.1 %

Shares of OMER stock opened at $10.00 on Monday. Omeros has a twelve month low of $2.61 and a twelve month high of $13.60. The stock’s fifty day simple moving average is $7.33 and its 200 day simple moving average is $5.28. The firm has a market capitalization of $579.50 million, a P/E ratio of -4.33 and a beta of 1.96.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its position in shares of Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 51,873 shares in the last quarter. Geode Capital Management LLC increased its stake in Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after purchasing an additional 6,839 shares in the last quarter. MML Investors Services LLC raised its holdings in Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares during the last quarter. Jane Street Group LLC raised its holdings in Omeros by 15.9% during the third quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 8,010 shares during the last quarter. Finally, Wellington Management Group LLP bought a new stake in shares of Omeros during the third quarter worth about $305,000. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.